Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients… (NCT07279220) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture
China238 participantsStarted 2025-12-29
Plain-language summary
The purpose of this study is to verify the safety and effectiveness of the Vascular Closure Device manufactured by Shanghai Bomaian Medical Technology Co., Ltd. for femoral artery hemostasis in patients of femoral artery puncture.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18\~80, male or non-pregnant female;
✓. Subjects undergoing interventional diagnostic or therapeutic procedures via femoral artery puncture;
✓. Subjects using 5F to 8F sheaths during the procedure (Note: Subjects using 5F-7F sheaths will enter the main randomized controlled cohort, while subjects using 8F sheaths will directly enter the single-arm observational cohort);
✓. Subjects or their legally authorized representatives can understand the purpose of the trial, voluntarily participate in the trial and sign informed consent form, and be able and willing to comply with follow-ups and related procedures.
Exclusion criteria
✕. Subjects with femoral artery occlusion or visually estimated lumen diameter \<5mm;
✕. Subjects with prior surgical procedures, percutaneous transluminal angioplasty (PTA), stent placement, or vascular grafts at the access site;
✕. Subjects with visible calcification at the access site, clinically significant peripheral vascular disease (requiring intervention), or stent implantation ≤1cm from the puncture site;
✕. Subjects whose puncture site is above the lowest edge of the inferior epigastric artery and/or above the inguinal ligament as identified by skeletal markers;
✕. Subjects with posterior wall vascular puncture or multiple femoral artery punctures due to difficulty in obtaining vascular access;
✕. Patients with pathological obesity (BMI \>40 kg/m²);
What they're measuring
1
Device Success Rate
Timeframe: Intra-procedure
Trial details
NCT IDNCT07279220
SponsorShanghai Bomaian Medical Technology Co., Ltd
✕. Subjects with pre-existing access site complications (hematoma, pseudoaneurysm, arteriovenous fistula, dissection, etc) or any procedure-related complications that may affect recovery, ambulation, or discharge timing;
✕. Subjects with acute ST-segment elevation myocardial infarction within 48 hours prior to the procedure;